Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial

Ola Landgren, Malin Hultcrantz, Benjamin Diamond, Alexander M. Lesokhin, Sham Mailankody, Hani Hassoun, Carlyn Tan, Urvi A. Shah, Sydney X. Lu, Meghan Salcedo, Kelly Werner, Jenna Rispoli, Julia Caple, Allison Sams, Dennis Verducci, Katie Jones, Isabel Concepcion, Amanda Ciardello, Aisara Chansakul, Julia SchlossmanElizabet Tavitian, Tala Shekarkhand, Angela Harrison, Casey Piacentini, Even H. Rustad, Venkata Yellapantula, Kylee Maclaughlan, Francesco Maura, Heather J. Landau, Michael Scordo, David J. Chung, Gunjan Shah, Oscar B. Lahoud, Katie Thoren, Kazunori Murata, Lakshmi Ramanathan, Maria E. Arcila, Caleb Ho, Mikhail Roshal, Ahmet Dogan, Andriy Derkach, Sergio A. Giralt, Neha Korde

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences